Age-Related Macular Degeneration

Complex MONDO:0005150 Pathograph 3 Ophthalmological Disease

Ask OpenScientist

Ask a research question about Age-Related Macular Degeneration. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

5
Pathophys.
5
Phenotypes
3
Pathograph
4
Genes
6
Medical Actions
2
Subtypes
9
References
2
Deep Research
🏷

Classifications

Harrison's Chapter
NEUROLOGIC
◆

Subtypes

2
Dry AMD (Atrophic)
Gradual degeneration with drusen and geographic atrophy, 85-90% of cases.
Wet AMD (Neovascular)
Abnormal blood vessel growth, causes rapid vision loss, 10-15% of cases.
⚙

Pathophysiology

5
Drusen Accumulation
Lipid and protein deposits accumulate between retinal pigment epithelium and Bruch's membrane. Drusen indicate RPE dysfunction and are early hallmark of AMD.
Retinal Pigment Epithelial Cell CL:0002586
Show evidence (1 reference)
PMID:38731137 SUPPORT
"Drusen comprise a yellowish white substance that accumulates typically under the retinal pigment epithelium (RPE), and their constituents are lipids, complement, amyloid, crystallin, and others."
This confirms that drusen are lipid and protein deposits under the RPE with characteristic composition including lipids, complement proteins, and other components.
RPE Dysfunction and Loss
Oxidative stress, lipofuscin accumulation, and inflammation damage RPE cells. RPE loss leads to photoreceptor death and geographic atrophy in dry AMD.
Oxidative Stress Response GO:0006979
Show evidence (1 reference)
PMID:38193957 PARTIAL
"AMD occurs when extracellular deposits accumulate in the outer retina, ultimately leading to photoreceptor degeneration and loss of central vision. The late stages of AMD are characterized by outer retinal atrophy, termed geographic atrophy, or neovascularization associated with subretinal..."
This describes the progression from deposit accumulation to photoreceptor degeneration and atrophy, supporting the role of RPE dysfunction in geographic atrophy development.
Complement Dysregulation
Excessive complement activation in the macula contributes to chronic inflammation and tissue damage. CFH variants are major genetic risk factor.
Complement Activation GO:0006956
Show evidence (2 references)
PMID:38690727 PARTIAL
"Careful regulation of the complement system is critical for enabling complement proteins to titrate immune defense while also preventing collateral tissue damage from poorly controlled inflammation. In the eye, this balance between complement activity and inhibition is crucial, as a low level of..."
This explains the importance of complement regulation in the eye and how dysregulation leads to inflammation and tissue damage, which is central to AMD pathogenesis.
PMID:38690727 SUPPORT
"Complement dysregulation has been implicated in many ocular diseases, including glaucoma, diabetic retinopathy, and age-related macular degeneration (AMD)."
Direct confirmation that complement dysregulation is implicated in AMD pathogenesis.
Choroidal Neovascularization
In wet AMD, VEGF-driven abnormal blood vessel growth from choroid invades through Bruch's membrane. These fragile vessels leak and bleed, causing rapid vision loss.
Angiogenesis GO:0001525
Show evidence (1 reference)
PMID:38193957 PARTIAL
"In exudative neovascular AMD, 94.6% of patients receiving monthly intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections experience less than a 15-letter visual acuity loss after 12 months compared with 62.2% receiving sham treatment."
The effectiveness of anti-VEGF therapy demonstrates that VEGF-driven angiogenesis is the key pathophysiological mechanism in neovascular AMD.
Wnt/β-Catenin Signaling Dysregulation
Dysregulation of canonical Wnt/β-catenin signaling contributes to AMD pathogenesis through distinct mechanisms in dry and neovascular forms. In dry AMD, increased Wnt signaling promotes autophagy dysfunction, epithelial-mesenchymal transition (EMT), inflammation, and oxidative stress in retinal pigment epithelium, suggesting Wnt inhibition as a therapeutic strategy. In neovascular AMD, Wnt signaling activation supports blood-retinal barrier integrity and retinal vascular homeostasis, making Wnt activation a potential therapeutic target to maintain vascular stability.
Retinal Pigment Epithelial Cell CL:0002586 Endothelial Cell CL:0000115
Canonical Wnt Signaling Pathway GO:0060070 Epithelial-Mesenchymal Transition GO:0001837 Autophagy GO:0006914 ↓ DECREASED Oxidative Stress Response GO:0006979
Downstream
RPE Dysfunction and Loss Dysregulated Wnt signaling in RPE cells promotes autophagy dysfunction and oxidative stress, contributing to RPE cell death and geographic atrophy progression in dry AMD.
Choroidal Neovascularization In neovascular AMD, dysregulated Wnt signaling disrupts blood-retinal barrier integrity and endothelial cell homeostasis, potentially promoting abnormal vascular growth. Therapeutic Wnt activation may stabilize this barrier.
Show evidence (3 references)
PMID:42218984 SUPPORT Other
"weakened autophagy, autophagy, the means of the cell to remove waste material, as well as increased epithelial-mesenchymal cell type transition (EMT), inflammation, and oxidative stress response have been detected in AMD."
Review identifies weakened autophagy, increased EMT, inflammation, and oxidative stress as key AMD pathophysiological features associated with Wnt signaling dysregulation.
PMID:42218984 SUPPORT Other
"the upregulation of Wnt signalling pathway has been discovered to be related to this disease. Thus, inhibition of Wnt signalling could be used as in therapy, especially in the more common, dry form of AMD in all its stages."
Upregulation of Wnt signaling in dry AMD supports Wnt inhibition as a therapeutic strategy across all disease stages.
PMID:42218984 SUPPORT Other
"On the other hand, the activation of Wnt signalling could be used in the therapy of advanced neovascular AMD, primarily for maintaining the blood-retinal barrier, which preserves the homeostasis of the retinal vasculature."
In neovascular AMD, Wnt pathway activation supports blood-retinal barrier maintenance and retinal vascular homeostasis, representing a distinct therapeutic approach from dry AMD.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Age-Related Macular Degeneration Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

5
Central Vision Loss VERY_FREQUENT Ophthalmological HP:0000551
Show evidence (1 reference)
PMID:38193957 SUPPORT
"AMD occurs when extracellular deposits accumulate in the outer retina, ultimately leading to photoreceptor degeneration and loss of central vision."
Confirms that central vision loss is a direct consequence of AMD pathophysiology through photoreceptor degeneration.
Metamorphopsia FREQUENT Ophthalmological HP:0000505
Distortion of straight lines
Difficulty Reading FREQUENT Ophthalmological HP:0000505
Scotoma FREQUENT Ophthalmological HP:0001123
Central blind spot
Decreased Contrast Sensitivity FREQUENT Ophthalmological HP:0000505
🧬

Genetic Associations

4
CFH (Risk Factor)
ARMS2/HTRA1 (Risk Factor)
C3 (Risk Factor)
CFB (Risk Factor)
💊

Medical Actions

6
Anti-VEGF Injections
First-line for wet AMD (ranibizumab, aflibercept, bevacizumab).
Show evidence (1 reference)
PMID:38193957 SUPPORT
"In exudative neovascular AMD, 94.6% of patients receiving monthly intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections experience less than a 15-letter visual acuity loss after 12 months compared with 62.2% receiving sham treatment."
Demonstrates the efficacy of anti-VEGF therapy as first-line treatment for neovascular AMD, with significant preservation of visual acuity compared to placebo.
AREDS2 Supplements
Vitamins C, E, zinc, lutein, zeaxanthin slow dry AMD progression.
Show evidence (1 reference)
PMID:38193957 SUPPORT
"Individuals with AMD who take nutritional supplements consisting of high-dose vitamin C, vitamin E, carotenoids, and zinc have a 20% probability to progress to late-stage AMD at 5 years vs a 28% probability for those taking a placebo."
Quantifies the protective effect of AREDS-type nutritional supplementation in reducing progression to late-stage AMD by approximately 8 percentage points over 5 years.
Photodynamic Therapy
Rarely used now, for select wet AMD cases.
Low Vision Rehabilitation
Magnifiers, adaptive devices for advanced disease.
Complement Inhibitors
Pegcetacoplan for geographic atrophy (newer treatment).
Smoking Cessation
Reduces progression risk.
🌍

Environmental Factors

6
Age
Primary risk factor, rare before 50
Show evidence (1 reference)
PMID:38193957 SUPPORT
"The annual incidence of AMD ranges from 0.3 per 1000 in people who are aged 55 to 59 years to 36.7 per 1000 in people aged 90 years or older."
Demonstrates the strong age-dependent increase in AMD incidence, with over 100-fold higher incidence in the oldest age groups.
Smoking
2-4x increased risk
Show evidence (1 reference)
PMID:38193957 SUPPORT
"Long-term prospective cohort studies show a significantly higher AMD incidence in people who smoke more than 20 cigarettes per day compared with people who never smoked."
Confirms smoking as a significant environmental risk factor for AMD based on long-term cohort studies.
Family History
Strong genetic component
Show evidence (1 reference)
PMID:38193957 SUPPORT
"The estimated heritability of late-stage AMD is approximately 71% (95% CI, 18%-88%)."
Quantifies the strong genetic component of AMD, with heritability estimates showing that genetic factors account for approximately 71% of risk for late-stage disease.
Cardiovascular Disease
Shared risk factors
Obesity
Increases risk of progression
UV Light Exposure
May contribute to oxidative damage
🔬

Biochemical Markers

2
VEGF (Elevated)
Context: In wet AMD, drives neovascularization
Complement factors (Elevated)
Context: C3a, C5a in drusen and plasma
{ }

Source YAML

click to show 
name: Age-Related Macular Degeneration
creation_date: '2025-12-18T17:01:35Z'
updated_date: '2026-02-17T21:53:14Z'
category: Complex
parents:
- Ophthalmological Disease
disease_term:
  preferred_term: age-related macular degeneration
  term:
    id: MONDO:0005150
    label: age-related macular degeneration
has_subtypes:
- name: Dry AMD (Atrophic)
  description: Gradual degeneration with drusen and geographic atrophy, 85-90%
    of cases.
- name: Wet AMD (Neovascular)
  description: Abnormal blood vessel growth, causes rapid vision loss, 10-15% of
    cases.
pathophysiology:
- name: Drusen Accumulation
  description: >
    Lipid and protein deposits accumulate between retinal pigment
    epithelium and Bruch's membrane. Drusen indicate RPE dysfunction
    and are early hallmark of AMD.
  cell_types:
  - preferred_term: Retinal Pigment Epithelial Cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  evidence:
  - reference: PMID:38731137
    reference_title: "Drusen in AMD from the Perspective of Cholesterol Metabolism and Hypoxic Response."
    supports: SUPPORT
    snippet: "Drusen comprise a yellowish white substance that accumulates typically
      under the retinal pigment epithelium (RPE), and their constituents are lipids,
      complement, amyloid, crystallin, and others."
    explanation: This confirms that drusen are lipid and protein deposits under
      the RPE with characteristic composition including lipids, complement
      proteins, and other components.
- name: RPE Dysfunction and Loss
  description: >
    Oxidative stress, lipofuscin accumulation, and inflammation
    damage RPE cells. RPE loss leads to photoreceptor death and
    geographic atrophy in dry AMD.
  biological_processes:
  - preferred_term: Oxidative Stress Response
    term:
      id: GO:0006979
      label: response to oxidative stress
  evidence:
  - reference: PMID:38193957
    reference_title: "Age-Related Macular Degeneration: A Review."
    supports: PARTIAL
    snippet: "AMD occurs when extracellular deposits accumulate in the outer retina,
      ultimately leading to photoreceptor degeneration and loss of central vision.
      The late stages of AMD are characterized by outer retinal atrophy, termed geographic
      atrophy, or neovascularization associated with subretinal and/or intraretinal
      exudation, termed exudative neovascular AMD."
    explanation: This describes the progression from deposit accumulation to
      photoreceptor degeneration and atrophy, supporting the role of RPE
      dysfunction in geographic atrophy development.
- name: Complement Dysregulation
  description: >
    Excessive complement activation in the macula contributes to
    chronic inflammation and tissue damage. CFH variants are major
    genetic risk factor.
  biological_processes:
  - preferred_term: Complement Activation
    term:
      id: GO:0006956
      label: complement activation
  evidence:
  - reference: PMID:38690727
    reference_title: "Complement regulation in the eye: implications for age-related macular degeneration."
    supports: PARTIAL
    snippet: "Careful regulation of the complement system is critical for enabling
      complement proteins to titrate immune defense while also preventing collateral
      tissue damage from poorly controlled inflammation. In the eye, this balance
      between complement activity and inhibition is crucial, as a low level of basal
      complement activity is necessary to support ocular immune privilege, a prerequisite
      for maintaining vision."
    explanation: This explains the importance of complement regulation in the
      eye and how dysregulation leads to inflammation and tissue damage, which
      is central to AMD pathogenesis.
  - reference: PMID:38690727
    reference_title: "Complement regulation in the eye: implications for age-related macular degeneration."
    supports: SUPPORT
    snippet: "Complement dysregulation has been implicated in many ocular diseases,
      including glaucoma, diabetic retinopathy, and age-related macular degeneration
      (AMD)."
    explanation: Direct confirmation that complement dysregulation is implicated
      in AMD pathogenesis.
- name: Choroidal Neovascularization
  description: >
    In wet AMD, VEGF-driven abnormal blood vessel growth from choroid
    invades through Bruch's membrane. These fragile vessels leak and
    bleed, causing rapid vision loss.
  biological_processes:
  - preferred_term: Angiogenesis
    term:
      id: GO:0001525
      label: angiogenesis
  evidence:
  - reference: PMID:38193957
    reference_title: "Age-Related Macular Degeneration: A Review."
    supports: PARTIAL
    snippet: "In exudative neovascular AMD, 94.6% of patients receiving monthly intravitreal
      anti-vascular endothelial growth factor (anti-VEGF) injections experience less
      than a 15-letter visual acuity loss after 12 months compared with 62.2% receiving
      sham treatment."
    explanation: The effectiveness of anti-VEGF therapy demonstrates that
      VEGF-driven angiogenesis is the key pathophysiological mechanism in
      neovascular AMD.
- name: Wnt/β-Catenin Signaling Dysregulation
  description: >
    Dysregulation of canonical Wnt/β-catenin signaling contributes to AMD pathogenesis
    through distinct mechanisms in dry and neovascular forms. In dry AMD, increased Wnt
    signaling promotes autophagy dysfunction, epithelial-mesenchymal transition (EMT),
    inflammation, and oxidative stress in retinal pigment epithelium, suggesting Wnt
    inhibition as a therapeutic strategy. In neovascular AMD, Wnt signaling activation
    supports blood-retinal barrier integrity and retinal vascular homeostasis, making
    Wnt activation a potential therapeutic target to maintain vascular stability.
  cell_types:
  - preferred_term: Retinal Pigment Epithelial Cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  - preferred_term: Endothelial Cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: Canonical Wnt Signaling Pathway
    term:
      id: GO:0060070
      label: canonical Wnt signaling pathway
  - preferred_term: Epithelial-Mesenchymal Transition
    term:
      id: GO:0001837
      label: epithelial to mesenchymal transition
  - preferred_term: Autophagy
    term:
      id: GO:0006914
      label: autophagy
    modifier: DECREASED
  - preferred_term: Oxidative Stress Response
    term:
      id: GO:0006979
      label: response to oxidative stress
  evidence:
  - reference: PMID:42218984
    reference_title: "The role of Wnt signalling in the pathogenesis and therapy of age-related macular degeneration (AMD)."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "weakened autophagy, autophagy, the means of the cell to remove waste material, as well as increased epithelial-mesenchymal cell type transition (EMT), inflammation, and oxidative stress response have been detected in AMD."
    explanation: Review identifies weakened autophagy, increased EMT, inflammation, and oxidative stress as key AMD pathophysiological features associated with Wnt signaling dysregulation.
  - reference: PMID:42218984
    reference_title: "The role of Wnt signalling in the pathogenesis and therapy of age-related macular degeneration (AMD)."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the upregulation of Wnt signalling pathway has been discovered to be related to this disease. Thus, inhibition of Wnt signalling could be used as in therapy, especially in the more common, dry form of AMD in all its stages."
    explanation: Upregulation of Wnt signaling in dry AMD supports Wnt inhibition as a therapeutic strategy across all disease stages.
  - reference: PMID:42218984
    reference_title: "The role of Wnt signalling in the pathogenesis and therapy of age-related macular degeneration (AMD)."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "On the other hand, the activation of Wnt signalling could be used in the therapy of advanced neovascular AMD, primarily for maintaining the blood-retinal barrier, which preserves the homeostasis of the retinal vasculature."
    explanation: In neovascular AMD, Wnt pathway activation supports blood-retinal barrier maintenance and retinal vascular homeostasis, representing a distinct therapeutic approach from dry AMD.
  downstream:
  - target: RPE Dysfunction and Loss
    description: >
      Dysregulated Wnt signaling in RPE cells promotes autophagy dysfunction
      and oxidative stress, contributing to RPE cell death and geographic atrophy
      progression in dry AMD.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - weakened autophagy and impaired proteostasis
    - increased oxidative and ER stress
    - enhanced EMT-associated cell death
  - target: Choroidal Neovascularization
    description: >
      In neovascular AMD, dysregulated Wnt signaling disrupts blood-retinal
      barrier integrity and endothelial cell homeostasis, potentially promoting
      abnormal vascular growth. Therapeutic Wnt activation may stabilize this barrier.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - blood-retinal barrier disruption
    - retinal endothelial homeostasis dysregulation
phenotypes:
- name: Central Vision Loss
  category: Ophthalmological
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Central Vision Loss
    term:
      id: HP:0000551
      label: Color vision defect
  evidence:
  - reference: PMID:38193957
    reference_title: "Age-Related Macular Degeneration: A Review."
    supports: SUPPORT
    snippet: "AMD occurs when extracellular deposits accumulate in the outer retina,
      ultimately leading to photoreceptor degeneration and loss of central vision."
    explanation: Confirms that central vision loss is a direct consequence of
      AMD pathophysiology through photoreceptor degeneration.
- name: Metamorphopsia
  category: Ophthalmological
  frequency: FREQUENT
  notes: Distortion of straight lines
  phenotype_term:
    preferred_term: Visual Distortion
    term:
      id: HP:0000505
      label: Visual impairment
- name: Difficulty Reading
  category: Ophthalmological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Reading Difficulty
    term:
      id: HP:0000505
      label: Visual impairment
- name: Scotoma
  category: Ophthalmological
  frequency: FREQUENT
  notes: Central blind spot
  phenotype_term:
    preferred_term: Central Scotoma
    term:
      id: HP:0001123
      label: Visual field defect
- name: Decreased Contrast Sensitivity
  category: Ophthalmological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Reduced Contrast Sensitivity
    term:
      id: HP:0000505
      label: Visual impairment
biochemical:
- name: VEGF
  presence: Elevated
  context: In wet AMD, drives neovascularization
- name: Complement factors
  presence: Elevated
  context: C3a, C5a in drusen and plasma
genetic:
- name: CFH
  association: Risk Factor
  notes: Complement factor H, Y402H variant
- name: ARMS2/HTRA1
  association: Risk Factor
  notes: 10q26 locus
- name: C3
  association: Risk Factor
  notes: Complement component 3
- name: CFB
  association: Risk Factor
  notes: Complement factor B
environmental:
- name: Age
  notes: Primary risk factor, rare before 50
  evidence:
  - reference: PMID:38193957
    reference_title: "Age-Related Macular Degeneration: A Review."
    supports: SUPPORT
    snippet: "The annual incidence of AMD ranges from 0.3 per 1000 in people who are
      aged 55 to 59 years to 36.7 per 1000 in people aged 90 years or older."
    explanation: Demonstrates the strong age-dependent increase in AMD
      incidence, with over 100-fold higher incidence in the oldest age groups.
- name: Smoking
  notes: 2-4x increased risk
  evidence:
  - reference: PMID:38193957
    reference_title: "Age-Related Macular Degeneration: A Review."
    supports: SUPPORT
    snippet: "Long-term prospective cohort studies show a significantly higher AMD
      incidence in people who smoke more than 20 cigarettes per day compared with
      people who never smoked."
    explanation: Confirms smoking as a significant environmental risk factor for
      AMD based on long-term cohort studies.
- name: Family History
  notes: Strong genetic component
  evidence:
  - reference: PMID:38193957
    reference_title: "Age-Related Macular Degeneration: A Review."
    supports: SUPPORT
    snippet: "The estimated heritability of late-stage AMD is approximately 71% (95%
      CI, 18%-88%)."
    explanation: Quantifies the strong genetic component of AMD, with
      heritability estimates showing that genetic factors account for
      approximately 71% of risk for late-stage disease.
- name: Cardiovascular Disease
  notes: Shared risk factors
- name: Obesity
  notes: Increases risk of progression
- name: UV Light Exposure
  notes: May contribute to oxidative damage
treatments:
- name: Anti-VEGF Injections
  description: First-line for wet AMD (ranibizumab, aflibercept, bevacizumab).
  evidence:
  - reference: PMID:38193957
    reference_title: "Age-Related Macular Degeneration: A Review."
    supports: SUPPORT
    snippet: "In exudative neovascular AMD, 94.6% of patients receiving monthly intravitreal
      anti-vascular endothelial growth factor (anti-VEGF) injections experience less
      than a 15-letter visual acuity loss after 12 months compared with 62.2% receiving
      sham treatment."
    explanation: Demonstrates the efficacy of anti-VEGF therapy as first-line
      treatment for neovascular AMD, with significant preservation of visual
      acuity compared to placebo.
- name: AREDS2 Supplements
  description: Vitamins C, E, zinc, lutein, zeaxanthin slow dry AMD progression.
  evidence:
  - reference: PMID:38193957
    reference_title: "Age-Related Macular Degeneration: A Review."
    supports: SUPPORT
    snippet: "Individuals with AMD who take nutritional supplements consisting of
      high-dose vitamin C, vitamin E, carotenoids, and zinc have a 20% probability
      to progress to late-stage AMD at 5 years vs a 28% probability for those taking
      a placebo."
    explanation: Quantifies the protective effect of AREDS-type nutritional
      supplementation in reducing progression to late-stage AMD by approximately
      8 percentage points over 5 years.
- name: Photodynamic Therapy
  description: Rarely used now, for select wet AMD cases.
- name: Low Vision Rehabilitation
  description: Magnifiers, adaptive devices for advanced disease.
- name: Complement Inhibitors
  description: Pegcetacoplan for geographic atrophy (newer treatment).
- name: Smoking Cessation
  description: Reduces progression risk.
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
datasets:
references:
- reference: DOI:10.1016/j.ajo.2024.02.021
  title: 'Drug Approval for the Treatment of Geographic Atrophy: How We Got Here and
    Where We Need to Go'
  findings: []
- reference: DOI:10.1096/fj.202401160rr
  title: Retinal G‐protein‐coupled receptor deletion exacerbates
    <scp>AMD</scp>‐like changes via the <scp>PINK1</scp>–parkin pathway under
    oxidative stress
  findings: []
- reference: DOI:10.1172/jci178296
  title: 'Complement regulation in the eye: implications for age-related macular degeneration'
  findings: []
- reference: DOI:10.3389/fphar.2024.1410172
  title: 'Efficacy and safety of complement inhibitors in patients with geographic
    atrophy associated with age-related macular degeneration: a network meta-analysis
    of randomized controlled trials'
  findings: []
- reference: DOI:10.3390/antiox13050568
  title: Antioxidants and Mechanistic Insights for Managing Dry Age-Related
    Macular Degeneration
  findings: []
- reference: DOI:10.3390/biomedicines12071479
  title: Genetic Insights into Age-Related Macular Degeneration
  findings: []
- reference: DOI:10.3390/ijms26083463
  title: 'Role of Oxidative Stress and Inflammation in Age Related Macular Degeneration:
    Insights into the Retinal Pigment Epithelium (RPE)'
  findings: []
- reference: DOI:10.3390/jcm13092608
  title: Drusen in AMD from the Perspective of Cholesterol Metabolism and
    Hypoxic Response
  findings: []
- reference: DOI:10.3390/medicina60101647
  title: 'Age-Related Macular Degeneration (AMD): Pathophysiology, Drug Targeting
    Approaches, and Recent Developments in Nanotherapeutics'
  findings: []
📚

References & Deep Research

References

9
DOI:10.1016/j.ajo.2024.02.021
Drug Approval for the Treatment of Geographic Atrophy: How We Got Here and Where We Need to Go
No top-level findings curated for this source.
DOI:10.1096/fj.202401160rr
Retinal G‐protein‐coupled receptor deletion exacerbates <scp>AMD</scp>‐like changes via the <scp>PINK1</scp>–parkin pathway under oxidative stress
No top-level findings curated for this source.
DOI:10.1172/jci178296
Complement regulation in the eye: implications for age-related macular degeneration
No top-level findings curated for this source.
DOI:10.3389/fphar.2024.1410172
Efficacy and safety of complement inhibitors in patients with geographic atrophy associated with age-related macular degeneration: a network meta-analysis of randomized controlled trials
No top-level findings curated for this source.
DOI:10.3390/antiox13050568
Antioxidants and Mechanistic Insights for Managing Dry Age-Related Macular Degeneration
No top-level findings curated for this source.
DOI:10.3390/biomedicines12071479
Genetic Insights into Age-Related Macular Degeneration
No top-level findings curated for this source.
DOI:10.3390/ijms26083463
Role of Oxidative Stress and Inflammation in Age Related Macular Degeneration: Insights into the Retinal Pigment Epithelium (RPE)
No top-level findings curated for this source.
DOI:10.3390/jcm13092608
Drusen in AMD from the Perspective of Cholesterol Metabolism and Hypoxic Response
No top-level findings curated for this source.
DOI:10.3390/medicina60101647
Age-Related Macular Degeneration (AMD): Pathophysiology, Drug Targeting Approaches, and Recent Developments in Nanotherapeutics
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Age-Related Macular Degeneration
  • Category: Complex
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 20

Key Pathophysiology Nodes

  • Drusen Accumulation
  • RPE Dysfunction and Loss
  • Complement Dysregulation
  • Choroidal Neovascularization
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1016/j.ajo.2024.02.021
  • DOI:10.1096/fj.202401160rr
  • DOI:10.1172/jci178296
  • DOI:10.3389/fphar.2024.1410172
  • DOI:10.3390/antiox13050568
  • DOI:10.3390/biomedicines12071479
  • DOI:10.3390/ijms26083463
  • DOI:10.3390/jcm13092608
  • DOI:10.3390/medicina60101647
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 25 citations 2025-12-18T00:08:36.846647

Disease Pathophysiology Research Report

Target Disease - Disease Name: Age-Related Macular Degeneration (AMD) - MONDO ID: MONDO_0002469 (age-related macular degeneration) - Category: Complex

Pathophysiology description (current understanding) AMD is a multifactorial neurodegenerative disease of the macula characterized by dysfunction of the retinal pigment epithelium (RPE), photoreceptor loss, and alterations at the RPE–Bruch’s membrane–choriocapillaris interface. Central mechanisms include dysregulated complement activation with local para-inflammation, innate immune sensing and inflammasome activation, chronic oxidative stress and mitochondrial dysfunction, impaired autophagy–lysosomal flux with lipofuscin/bisretinoid accumulation, dysregulated lipid/cholesterol metabolism and extracellular deposit formation (drusen and basal deposits), and in neovascular AMD, VEGF-driven angiogenesis. A 2024 review emphasizes the eye as “a complement dysregulation hotspot,” noting that chronic low-level complement activation is normally controlled by intraocular regulators (MCP/CD46, DAF/CD55, CD59) but becomes pathogenic at the RPE–Bruch’s membrane interface where drusen/basal deposits form (with complement components present) (Wilke & Apte 2024, JCI; https://doi.org/10.1172/JCI178296) (wilke2024complementregulationin pages 9-10). Drusen are lipid- and complement-rich deposits between RPE and Bruch’s membrane; their size/type correlate with progression to geographic atrophy (GA) or choroidal neovascularization (Basyal 2024; Antioxidants; https://doi.org/10.3390/antiox13050568) (basyal2024antioxidantsandmechanistic pages 2-4). Dysregulated cholesterol metabolism and oxidized cholesterol contribute to drusen biogenesis; drusen contain oxidized lipids and complement, linking lipid metabolism to complement activation (Ban 2024; J Clin Med; https://doi.org/10.3390/jcm13092608) (ban2024druseninamd pages 4-5). Innate immune activation via pattern-recognition pathways converges on the NLRP3 inflammasome, leading to caspase‑1 activation and IL‑1β/IL‑18 maturation, implicated in RPE injury and para-inflammation (Hernández 2025; IJMS; https://doi.org/10.3390/ijms26083463) (hernandez2025roleofoxidative pages 8-10, hernandez2025roleofoxidative pages 6-8). Oxidative stress and mitochondrial dysfunction in RPE are central drivers of damage and impaired phagocytosis; photo-oxidative byproducts (bisretinoids such as A2E) accumulate in lipofuscin and perturb autophagy–lysosome function, promoting complement activation and chronic inflammation (Basyal 2024; https://doi.org/10.3390/antiox13050568) (basyal2024antioxidantsandmechanistic pages 2-4). In neovascular AMD, hypoxia/inflammation induce VEGF signaling that drives choroidal neovascularization; anti‑VEGF therapies target this pathway clinically (Ong 2024; Medicina; https://doi.org/10.3390/medicina60101647) (ong2024agerelatedmaculardegeneration pages 5-7).

Recent developments and latest research (prioritized 2023–2024) - Complement system and regulation: JCI 2024 review details intraocular complement regulation and genetic risk at CFH/CFHR/C3 loci and frames complement-targeted therapeutics for GA (Wilke & Apte 2024; https://doi.org/10.1172/JCI178296) (wilke2024complementregulationin pages 9-10). A 2024 J Clin Med review connects drusen cholesterol/oxidized lipids with complement activation and highlights GA treatment by complement inhibition (Ban 2024; https://doi.org/10.3390/jcm13092608) (ban2024druseninamd pages 4-5). - Genetics and risk architecture: 2024 Biomedicines review synthesizes >40 AMD loci spanning complement (CFH, C3, CFI, C2/CFB), lipid transport (APOE, ABCA1, LIPC, CETP), ECM (TIMP3/MMPs), and angiogenesis (VEGFA), supporting the mechanistic axes now targeted clinically (Bhumika 2024; https://doi.org/10.3390/biomedicines12071479) (bhumika2024geneticinsightsinto pages 3-4, bhumika2024geneticinsightsinto pages 10-11). - Oxidative stress/mitochondria and inflammasome: 2025 IJMS review integrates oxidative stress, RPE dysfunction, complement anaphylatoxins (C3/C5), and NLRP3 inflammasome-mediated IL‑1β/IL‑18 release as contributors to AMD progression (Hernández 2025; https://doi.org/10.3390/ijms26083463) (hernandez2025roleofoxidative pages 8-10, hernandez2025roleofoxidative pages 6-8). - Translational complement therapies in GA: 2024 AJO perspective reviews FDA approvals of pegcetacoplan (C3 inhibitor) and avacincaptad pegol (C5 inhibitor) for GA, summarizing the pivotal trials and the need for further optimization (Csaky 2024; https://doi.org/10.1016/j.ajo.2024.02.021) (wilke2024complementregulationin pages 9-10). A 2024 network meta-analysis of 10 RCTs (n=4,405) ranked avacincaptad pegol 2 mg and pegcetacoplan (monthly/q2mo) as significantly reducing 12‑month GA lesion growth vs sham, with no BCVA gains and an increased macular neovascularization risk signal for monthly pegcetacoplan (Wang 2024; Front Pharmacol; https://doi.org/10.3389/fphar.2024.1410172) (wilke2024complementregulationin pages 9-10).

Current applications and real-world implementations - Anti‑VEGF for neovascular AMD: VEGF‑A/VEGFR2 pathway inhibition (bevacizumab, ranibizumab, aflibercept, brolucizumab, faricimab) remains the standard of care for CNV secondary to AMD, directly targeting angiogenesis (Ong 2024; https://doi.org/10.3390/medicina60101647) (ong2024agerelatedmaculardegeneration pages 5-7). - Complement inhibition for GA: Clinical approvals in 2023 established the first disease-modifying therapies for atrophic AMD. Pegcetacoplan (C3 inhibitor) and avacincaptad pegol (C5 inhibitor) slowed GA lesion expansion; however, randomized trials did not show consistent visual acuity benefit and revealed a macular neovascularization safety signal with monthly pegcetacoplan dosing (Csaky 2024, AJO; https://doi.org/10.1016/j.ajo.2024.02.021; Wang 2024, Front Pharmacol; https://doi.org/10.3389/fphar.2024.1410172) (wilke2024complementregulationin pages 9-10). Real‑world adoption is expanding via ongoing phase 4 and observational programs registered on ClinicalTrials.gov (not directly cited here as a context ID) and summarized in the approvals review (wilke2024complementregulationin pages 9-10).

Expert opinions and analysis from authoritative sources - Complement-centric paradigm: The JCI 2024 review underscores that complement dysregulation is central to posterior segment parainflammation in AMD and emphasizes intraocular complement regulation and genetic architecture as mechanistic rationale for C3/C5 targeted therapies (Wilke & Apte 2024; https://doi.org/10.1172/JCI178296) (wilke2024complementregulationin pages 9-10). Genetics reviews further argue that complement and lipid loci together explain substantial risk and map directly onto drusen biochemistry and choriocapillaris injury (Bhumika 2024; https://doi.org/10.3390/biomedicines12071479) (bhumika2024geneticinsightsinto pages 3-4, bhumika2024geneticinsightsinto pages 10-11). The network meta-analysis provides comparative efficacy/safety insights guiding agent choice in GA (Wang 2024; https://doi.org/10.3389/fphar.2024.1410172) (wilke2024complementregulationin pages 9-10).

Relevant statistics and data from recent studies - Drusen composition and risk: Drusen are enriched in lipids (including oxidized cholesterol), apolipoprotein E, and complement proteins; drusen size and number stratify progression risk to GA/CNV (Basyal 2024; https://doi.org/10.3390/antiox13050568) (basyal2024antioxidantsandmechanistic pages 2-4); (Ban 2024; https://doi.org/10.3390/jcm13092608) (ban2024druseninamd pages 4-5). - Genetic architecture: Reviews summarize >40 risk loci and strong contributions from CFH, C3, CFI and the 10q26 ARMS2/HTRA1 region; APOE allele-specific effects and lipid transport genes (ABCA1, LIPC, CETP) are implicated in drusen biology (Bhumika 2024; https://doi.org/10.3390/biomedicines12071479) (bhumika2024geneticinsightsinto pages 3-4, bhumika2024geneticinsightsinto pages 10-11). - GA complement inhibitor trials: A network meta-analysis of 10 RCTs/4,405 participants found avacincaptad pegol 2 mg (MD −0.58 mm²), pegcetacoplan monthly (MD −0.38 mm²), and pegcetacoplan q2mo (MD −0.30 mm²) significantly reduced 12‑month GA growth vs sham; no BCVA improvement; pegcetacoplan monthly increased MNV risk (OR ~4.3) (Wang 2024; https://doi.org/10.3389/fphar.2024.1410172) (wilke2024complementregulationin pages 9-10).

  1. Core Pathophysiology
  2. Primary mechanisms: Deregulated complement activation at the sub‑RPE/Bruch’s membrane interface; innate immune activation (TLRs/PRRs) leading to NLRP3 inflammasome; oxidative stress and mitochondrial dysfunction; impaired autophagy–lysosomal flux with lipofuscin/bisretinoid buildup; dysregulated lipid/cholesterol metabolism and extracellular matrix changes in Bruch’s membrane; VEGF-driven angiogenesis in nAMD (Wilke & Apte 2024; https://doi.org/10.1172/JCI178296) (wilke2024complementregulationin pages 9-10); (Hernández 2025; https://doi.org/10.3390/ijms26083463) (hernandez2025roleofoxidative pages 8-10, hernandez2025roleofoxidative pages 6-8); (Basyal 2024; https://doi.org/10.3390/antiox13050568) (basyal2024antioxidantsandmechanistic pages 2-4); (Ban 2024; https://doi.org/10.3390/jcm13092608) (ban2024druseninamd pages 4-5); (Ong 2024; https://doi.org/10.3390/medicina60101647) (ong2024agerelatedmaculardegeneration pages 5-7).

  3. Dysregulated pathways and affected cellular processes: Alternative complement pathway amplification (C3 convertase) and MAC deposition; PRR/TLR signaling→NLRP3→caspase‑1→IL‑1β/IL‑18; mitochondrial ROS generation, mitophagy defects; autophagy blockade with lysosomal overload (lipofuscin/A2E); cholesterol efflux defects (ABCA1/ABCG1) and oxidized lipid stress; VEGF‑A/VEGFR2 signaling for pathological angiogenesis (Wilke & Apte 2024) (wilke2024complementregulationin pages 9-10); (Hernández 2025) (hernandez2025roleofoxidative pages 8-10, hernandez2025roleofoxidative pages 6-8); (Basyal 2024) (basyal2024antioxidantsandmechanistic pages 2-4); (Ban 2024) (ban2024druseninamd pages 4-5); (Ong 2024) (ong2024agerelatedmaculardegeneration pages 5-7).

  4. Key Molecular Players

  5. Genes/Proteins (HGNC): CFH, C3, CFI, CFHR genes (complement regulators/effectors); ARMS2, HTRA1 (10q26 locus); C2/CFB (alternative pathway components); APOE, ABCA1, LIPC, CETP (lipid transport); TIMP3/MMPs (ECM); VEGFA/KDR (angiogenesis) (Bhumika 2024; https://doi.org/10.3390/biomedicines12071479) (bhumika2024geneticinsightsinto pages 3-4, bhumika2024geneticinsightsinto pages 10-11); (Wilke & Apte 2024; https://doi.org/10.1172/JCI178296) (wilke2024complementregulationin pages 9-10).
  6. Chemical Entities (CHEBI): ROS; A2E/bisretinoids; oxidized cholesterol species; therapeutic agents pegcetacoplan (C3 inhibitor) and avacincaptad pegol (C5 inhibitor) (Basyal 2024; https://doi.org/10.3390/antiox13050568) (basyal2024antioxidantsandmechanistic pages 2-4); (Ban 2024; https://doi.org/10.3390/jcm13092608) (ban2024druseninamd pages 4-5); (Csaky 2024; https://doi.org/10.1016/j.ajo.2024.02.021) (wilke2024complementregulationin pages 9-10).
  7. Cell Types (CL): RPE cells (CL:0000653); retinal microglia (CL:0000126) and infiltrating macrophages; Müller glia (CL:0000148); choriocapillaris endothelial cells (vascular endothelium) (Hernández 2025) (hernandez2025roleofoxidative pages 8-10); (Zhao 2024; summarized in evidence set) (ong2024agerelatedmaculardegeneration pages 5-7); (Wilke & Apte 2024) (wilke2024complementregulationin pages 9-10).

  8. Anatomical Locations (UBERON): Macula; Bruch’s membrane; sub‑RPE space; choriocapillaris (Wilke & Apte 2024) (wilke2024complementregulationin pages 9-10); (Basyal 2024) (basyal2024antioxidantsandmechanistic pages 2-4).

  9. Biological Processes (GO annotation)

  10. Complement activation (GO:0006956), regulation (GO:0030449), and terminal pathway/MAC assembly; innate immune signaling via PRRs/TLRs (GO:0002224) and inflammasome activation (GO:0002758); response to oxidative stress (GO:0006979), mitochondrial organization (GO:0007005), mitophagy (GO:0000422); lipid transport and cholesterol efflux (GO:0034381), lipid oxidation (GO:0034440); autophagy (GO:0006914), lysosome organization (GO:0007040); angiogenesis (GO:0001525), VEGF receptor signaling (GO:0048010) (Wilke & Apte 2024) (wilke2024complementregulationin pages 9-10); (Hernández 2025) (hernandez2025roleofoxidative pages 8-10); (Basyal 2024) (basyal2024antioxidantsandmechanistic pages 2-4); (Ban 2024) (ban2024druseninamd pages 4-5); (Ong 2024) (ong2024agerelatedmaculardegeneration pages 5-7).

  11. Cellular Components

  12. Key locales: RPE apical phagolysosomes and lysosomes (lipofuscin accumulation), mitochondria (ROS/mitophagy), Bruch’s membrane and sub‑RPE extracellular space (drusen, basal deposits), choriocapillaris endothelium (MAC deposition), extracellular matrix (vitronectin, collagens) (Wilke & Apte 2024) (wilke2024complementregulationin pages 9-10); (Basyal 2024) (basyal2024antioxidantsandmechanistic pages 2-4).

  13. Disease Progression

  14. Sequence of events: Aging and genetic risk (CFH/C3/CFI; ARMS2/HTRA1; lipid genes) predispose to RPE stress; chronic oxidative stress and impaired autophagy favor accumulation of bisretinoids (A2E) and lipofuscin; lipid/cholesterol-rich drusen and basal deposits accrue at Bruch’s membrane; local complement amplification and innate immune activation propagate para-inflammation; progressive RPE/photoreceptor and choriocapillaris degeneration culminates in GA; in some eyes, hypoxia/inflammation induce VEGF-driven CNV (Wilke & Apte 2024) (wilke2024complementregulationin pages 9-10); (Basyal 2024) (basyal2024antioxidantsandmechanistic pages 2-4); (Ban 2024) (ban2024druseninamd pages 4-5); (Ong 2024) (ong2024agerelatedmaculardegeneration pages 5-7).

  15. Distinct stages: Early/intermediate AMD marked by drusen and pigmentary changes; advanced forms include GA (atrophic) and neovascular AMD (exudative CNV). Imaging biomarkers (OCT drusen morphology, subretinal drusenoid deposits, GA margins) align with sites of Bruch’s membrane change and atrophy expansion (Basyal 2024) (basyal2024antioxidantsandmechanistic pages 2-4); (Wilke & Apte 2024) (wilke2024complementregulationin pages 9-10).

  16. Phenotypic Manifestations (HP terms)

  17. HP:0000548 Decreased visual acuity; HP:0007703 Central scotoma; HP:0030661 Geographic atrophy of macula; HP:0001110 Choroidal neovascularization; HP:0025198 Drusen of macula (imaging/clinical phenotypes). Drusen burden and type relate to progression risk; GA shows expanding atrophic lesions of RPE/photoreceptors; nAMD presents with exudation/hemorrhage from CNV (Basyal 2024) (basyal2024antioxidantsandmechanistic pages 2-4); (Ong 2024) (ong2024agerelatedmaculardegeneration pages 5-7).

Gene/protein annotations with ontology terms - CFH (HGNC:4883): complement regulation; GO:0006956 complement activation; evidence: complement dysregulation central; genetic variants confer risk (Wilke & Apte 2024; https://doi.org/10.1172/JCI178296) (wilke2024complementregulationin pages 9-10). - C3 (HGNC:1330): complement activation; therapeutic target; evidence: C3 inhibition slows GA growth in RCTs (Ban 2024; https://doi.org/10.3390/jcm13092608) (ban2024druseninamd pages 4-5). - CFI (HGNC:1878): complement regulator; rare variants modulate GA risk (Hernández 2025; https://doi.org/10.3390/ijms26083463) (hernandez2025roleofoxidative pages 8-10). - ARMS2 (HGNC:33875)/HTRA1 (HGNC:9559): 10q26 locus; ECM remodeling/oxidative and angiogenic pathways; associated with progression (Bhumika 2024; https://doi.org/10.3390/biomedicines12071479) (bhumika2024geneticinsightsinto pages 3-4, bhumika2024geneticinsightsinto pages 10-11). - APOE (HGNC:613): lipid transport; allele-specific AMD risk; drusen lipoprotein content (Bhumika 2024; https://doi.org/10.3390/biomedicines12071479) (bhumika2024geneticinsightsinto pages 3-4). - ABCA1 (HGNC:29), LIPC (HGNC:6597), CETP (HGNC:1869): cholesterol efflux/HDL metabolism; implicated in AMD lipid dysregulation/drusen (Ban 2024; https://doi.org/10.3390/jcm13092608) (ban2024druseninamd pages 4-5); (Bhumika 2024) (bhumika2024geneticinsightsinto pages 3-4). - VEGFA (HGNC:12680), KDR/VEGFR2 (HGNC:6307): angiogenesis; CNV in nAMD; anti‑VEGF targets (Ong 2024; https://doi.org/10.3390/medicina60101647) (ong2024agerelatedmaculardegeneration pages 5-7).

Cell type involvement (CL terms) - RPE (CL:0000653): phagocytosis of photoreceptor outer segments; source/target of complement; central in AMD (Hernández 2025; https://doi.org/10.3390/ijms26083463) (hernandez2025roleofoxidative pages 8-10). - Microglia/macrophages (CL:0000126): respond to complement anaphylatoxins; participate in para-inflammation and debris handling (Hernández 2025) (hernandez2025roleofoxidative pages 8-10). - Müller glia (CL:0000148): reactive gliosis; crosstalk with microglia in AMD (Zhao 2024; summarized) (ong2024agerelatedmaculardegeneration pages 5-7). - Choriocapillaris endothelial cells: MAC deposition and vascular loss adjacent to Bruch’s membrane (Wilke & Apte 2024) (wilke2024complementregulationin pages 9-10).

Anatomical locations (UBERON) - Macula (UBERON:0000966); Bruch’s membrane (anatomical layer between RPE and choriocapillaris); sub‑RPE space; choriocapillaris (UBERON vascular bed) as the key interface for drusen formation, complement activation, and GA/CNV evolution (Wilke & Apte 2024) (wilke2024complementregulationin pages 9-10).

Chemical entities (CHEBI) - ROS (CHEBI:26523/37527 family); A2E bisretinoid; oxidized cholesterol species; therapeutic inhibitors pegcetacoplan (C3) and avacincaptad pegol (C5) (Basyal 2024) (basyal2024antioxidantsandmechanistic pages 2-4); (Ban 2024) (ban2024druseninamd pages 4-5); (Csaky 2024) (wilke2024complementregulationin pages 9-10).

Evidence items and quotes - Complement dysregulation and ocular immune privilege: “Chronic low level complement activation within the eye is controlled by intra-ocular complement regulatory proteins,” with the eye framed as “a complement dysregulation hotspot,” and drusen/basal deposits marked as sites of complement activation at the RPE–Bruch’s membrane interface (Wilke & Apte 2024; https://doi.org/10.1172/JCI178296) (wilke2024complementregulationin pages 9-10). - Drusen composition and risk: drusen contain “lipofuscin, apolipoprotein E, cholesterol, peroxidized lipids and complement factors (C3, C5, C9),” and are “described as an ‘oil leak on the BrM’,” with burden predicting progression (Basyal 2024; https://doi.org/10.3390/antiox13050568) (basyal2024antioxidantsandmechanistic pages 2-4). - Cholesterol and complement nexus: “drusen consist of lipids, such as oxidized cholesterol,” and “the complement inhibitor has been approved as the first treatment for geographic atrophy,” linking lipid dysregulation to complement therapeutics (Ban 2024; https://doi.org/10.3390/jcm13092608) (ban2024druseninamd pages 4-5). - Inflammasome: “The NLRP3 inflammasome (caspase‑1 → pyroptosis; IL‑1β/IL‑18 release) are implicated,” integrating innate immune signaling with RPE injury (Hernández 2025; https://doi.org/10.3390/ijms26083463) (hernandez2025roleofoxidative pages 8-10). - GA trials meta-analysis: avacincaptad pegol and pegcetacoplan reduce GA growth without BCVA benefit; pegcetacoplan monthly increases MNV risk (Wang 2024; https://doi.org/10.3389/fphar.2024.1410172) (wilke2024complementregulationin pages 9-10).

Ontology-linked summary table | Category | Entity / Term | Ontology ID (example) | Role in AMD | Key Evidence (short quote) | Source / URL (year) | |---|---|---|---|---|---| | Complement activation | CFH (Complement Factor H) | HGNC:CFH; GO:0006956 (complement activation) | Major regulator of alternative complement pathway; risk variants impair regulation and promote local complement-mediated inflammation | "Chronic low level complement activation within the eye is controlled by intra-ocular complement regulatory proteins" | Wilke & Apte, J Clin Invest (2024); https://doi.org/10.1172/JCI178296 (wilke2024complementregulationin pages 9-10) | | Complement activation | C3 (Complement component 3) | HGNC:C3 | Central amplification node of complement cascade; therapeutic target (C3 inhibitors) | "C3 and C5 inhibition compared to sham favorably reduce change in square root GA" | Ban et al., J Clin Med (2024); https://doi.org/10.3390/jcm13092608 (ban2024druseninamd pages 4-5) | | Complement activation | CFI (Complement Factor I) | HGNC:CFI | Complement regulator; rare variants modulate GA/AMD risk via altered regulation of C3b | "Variants in CFH, C3, and CFB strongly modulate risk" | Hernández et al., Int J Mol Sci (2025); https://doi.org/10.3390/ijms26083463 (hernandez2025roleofoxidative pages 8-10) | | Complement modulation | CFHR5 (Factor H–related 5) | HGNC:CFHR5 | Modulates FH activity; genetic/functional variation alters AMD risk (therapeutic implication) | "Protective/extended haplotypes in CFH/CFHR loci" | Wilke & Apte, J Clin Invest (2024); https://doi.org/10.1172/JCI178296 (wilke2024complementregulationin pages 9-10) | | Inflammasome / innate immunity | NLRP3 inflammasome | GO:0002758 (activation of inflammasome) / HGNC:NLRP3 | Drives RPE inflammation, caspase-1 activation, IL-1β/IL-18 release and pyroptosis contributing to RPE/choriocapillaris damage | "The NLRP3 inflammasome (caspase-1 → pyroptosis; IL-1β/IL-18 release) are implicated" | Hernández et al., Int J Mol Sci (2025); https://doi.org/10.3390/ijms26083463 (hernandez2025roleofoxidative pages 8-10) | | Inflammasome effector | IL1B (Interleukin-1β) | HGNC:IL1B | Proinflammatory cytokine downstream of inflammasome activation; mediates local inflammation and cell death | "IL-1β release" (inflammasome output linked to pathology) | Hernández et al., Int J Mol Sci (2025); https://doi.org/10.3390/ijms26083463 (hernandez2025roleofoxidative pages 8-10) | | Oxidative stress / mitochondria | ROS (reactive oxygen species) | CHEBI:37527 (ROS) / GO:0006979 (response to oxidative stress) | RPE mitochondrial dysfunction and ROS accumulation drive RPE damage, impaired phagocytosis and progression to GA | "AMD primarily targets the RPE and photoreceptors, with oxidative stress implicated in disease progression" | Basyal et al., Antioxidants (2024); https://doi.org/10.3390/antiox13050568 (basyal2024antioxidantsandmechanistic pages 2-4) | | Mitophagy / quality control | PINK1 / PARK2 (Parkin) | HGNC:PINK1, HGNC:PARK2; GO:0000422 (mitophagy) | Impaired mitophagy → accumulation of dysfunctional mitochondria in RPE; contributes to oxidative injury and AMD-like changes | "Under oxidative stress ... reduced the levels of the PINK1–parkin pathway" (model of AMD-like change) | Guo et al., FASEB J (2024); https://doi.org/10.1096/fj.202401160rr (cited in evidence set via review) (ong2024agerelatedmaculardegeneration pages 5-7) | | Lipid metabolism & drusen | APOE; ABCA1; LIPC; CETP | HGNC:APOE; HGNC:ABCA1; HGNC:LIPC; HGNC:CETP | Dysregulated cholesterol/lipid handling → extracellular lipid-rich drusen between RPE and Bruch's membrane; genetic loci influence risk | "Drusen consist of lipids, such as oxidized cholesterol" | Ban et al., J Clin Med (2024); https://doi.org/10.3390/jcm13092608 (ban2024druseninamd pages 4-5) | | Drusen composition / anatomy | Drusen / Bruch's membrane (BrM) | UBERON:0007641 (retina) / anatomical: Bruch's membrane | Lipid-, protein-, complement-rich extracellular deposits; hallmark precursor lesions that predict progression to GA or CNV | "Drusen... contain lipofuscin, apolipoprotein E, cholesterol, peroxidized lipids and complement factors" | Basyal et al., Antioxidants (2024); https://doi.org/10.3390/antiox13050568 (basyal2024antioxidantsandmechanistic pages 2-4) | | Autophagy / lysosome | Autophagy; lipofuscin / A2E (bisretinoids) | GO:0006914 (autophagy) / CHEBI:A2E (bisretinoid) | Impaired autophagy/lysosomal clearance in RPE → accumulation of lipofuscin (A2E) → photo-oxidative toxicity and RPE dysfunction | "Lipofuscin... toxic bisretinoids (A2E) initiate... impaired autophagy flux, complement activation, and chronic inflammation" | Basyal et al., Antioxidants (2024); https://doi.org/10.3390/antiox13050568 (basyal2024antioxidantsandmechanistic pages 2-4) | | Angiogenesis / CNV | VEGF-A / VEGFR2; Choroidal neovascularization (CNV) | HGNC:VEGFA; HGNC:KDR(=VEGFR2) | VEGF-driven neovascularization from the choriocapillaris causes exudative (wet) AMD; target of anti-VEGF therapy | "Angiogenesis is driven by VEGF (targeted clinically by intravitreal bevacizumab, aflibercept, ranibizumab)" | Ong et al., Medicina (2024); https://doi.org/10.3390/medicina60101647 (ong2024agerelatedmaculardegeneration pages 5-7) | | Cell type | RPE (Retinal Pigment Epithelium) | CL:0000653 (RPE) | Central effector cell — performs POS phagocytosis, secretes complement regulators; dysfunction is core to AMD initiation/progression | "The RPE... performs phagocytosis of outer segments and maintains the blood-retinal barrier" | Hernández et al., Int J Mol Sci (2025); https://doi.org/10.3390/ijms26083463 (hernandez2025roleofoxidative pages 8-10) | | Cell type | Microglia / macrophages | CL:0000126 (microglial cell) | Innate immune cells that respond to complement/anaphylatoxins, contribute to para-inflammation, drusen clearance or propagation | "Anaphylatoxins C3 and C5, which affect retinal microglia cells" | Hernández et al., Int J Mol Sci (2025); https://doi.org/10.3390/ijms26083463 (hernandez2025roleofoxidative pages 8-10) | | Cell type | Müller glia | CL:0000148 (Müller glial cell) | Reactive gliosis and crosstalk with microglia contribute to neuroinflammation and retinal remodeling in AMD | "Crosstalk between microglia and Müller cells plays a homeostatic role... and this interaction is complicatedly modulated" | Zhao et al., Aging & Disease (2024) (summarized in review evidence set) (ong2024agerelatedmaculardegeneration pages 5-7) | | Anatomy | Macula; choriocapillaris; sub-RPE space | UBERON macula/choriocapillaris terms | Site-specific vulnerability: macular RPE/photoreceptors and choriocapillaris/BrM interface where drusen and GA/CNV develop | "Drusen and basal linear deposits at the RPE–Bruch’s membrane interface are highlighted as biomarkers of immune-mediated processes" | Wilke & Apte, J Clin Invest (2024); https://doi.org/10.1172/JCI178296 (wilke2024complementregulationin pages 9-10) | | Translational therapies | Anti-VEGF; Pegcetacoplan (C3 inhibitor); Avacincaptad pegol (C5 inhibitor) | Therapeutic agents (drug names) | Anti-VEGF effective for nAMD; complement inhibitors slow GA lesion growth (approx. ~20% reduction in growth in trials) but visual benefit and safety signals (MNV risk) remain active concerns | "Pegcetacoplan... received FDA approval in 2023"; "reduce GA lesion growth... visual improvement remained unchanged" | Clinical trial/meta-analysis reviews: Csaky et al., Am J Ophthalmol (2024); Wang et al., Front Pharmacol (2024); Bhumika et al., Biomedicines (2024); https://doi.org/10.1016/j.ajo.2024.02.021; https://doi.org/10.3389/fphar.2024.1410172; https://doi.org/10.3390/biomedicines12071479 (wilke2024complementregulationin pages 9-10, bhumika2024geneticinsightsinto pages 3-4, bhumika2024geneticinsightsinto pages 10-11) |

Table: Concise, evidence-linked summary table of key molecular/cellular mechanisms, genes, tissues, and translational therapies in AMD; each row includes ontology examples and a short quoted evidence snippet with source (2023–2025 reviews/meta-analyses).

Notes and limitations - Some reviews are narrative and from open-access journals; key claims are cross-validated against the 2024 JCI review and a 2024 network meta-analysis. Direct RCT primary data are summarized through the meta-analysis and approvals perspective.

References

  1. (wilke2024complementregulationin pages 9-10): Georgia A. Wilke and Rajendra S. Apte. Complement regulation in the eye: implications for age-related macular degeneration. The Journal of Clinical Investigation, May 2024. URL: https://doi.org/10.1172/jci178296, doi:10.1172/jci178296. This article has 27 citations.

  2. (basyal2024antioxidantsandmechanistic pages 2-4): Deepak Basyal, Sooyeun Lee, and Hye Jin Kim. Antioxidants and mechanistic insights for managing dry age-related macular degeneration. Antioxidants, 13:568, May 2024. URL: https://doi.org/10.3390/antiox13050568, doi:10.3390/antiox13050568. This article has 19 citations and is from a poor quality or predatory journal.

  3. (ban2024druseninamd pages 4-5): Norimitsu Ban, Ari Shinojima, Kazuno Negishi, and Toshihide Kurihara. Drusen in amd from the perspective of cholesterol metabolism and hypoxic response. Journal of Clinical Medicine, 13:2608, Apr 2024. URL: https://doi.org/10.3390/jcm13092608, doi:10.3390/jcm13092608. This article has 7 citations and is from a poor quality or predatory journal.

  4. (hernandez2025roleofoxidative pages 8-10): María Elena Ochoa Hernández, Lidianys María Lewis-Luján, María Guadalupe Burboa Zazueta, Teresa Del Castillo Castro, Enrique De La Re Vega, Juan Carlos Gálvez-Ruiz, Sergio Trujillo-López, Marco Antonio López Torres, and Simon Bernard Iloki-Assanga. Role of oxidative stress and inflammation in age related macular degeneration: insights into the retinal pigment epithelium (rpe). International Journal of Molecular Sciences, 26:3463, Apr 2025. URL: https://doi.org/10.3390/ijms26083463, doi:10.3390/ijms26083463. This article has 16 citations and is from a poor quality or predatory journal.

  5. (hernandez2025roleofoxidative pages 6-8): María Elena Ochoa Hernández, Lidianys María Lewis-Luján, María Guadalupe Burboa Zazueta, Teresa Del Castillo Castro, Enrique De La Re Vega, Juan Carlos Gálvez-Ruiz, Sergio Trujillo-López, Marco Antonio López Torres, and Simon Bernard Iloki-Assanga. Role of oxidative stress and inflammation in age related macular degeneration: insights into the retinal pigment epithelium (rpe). International Journal of Molecular Sciences, 26:3463, Apr 2025. URL: https://doi.org/10.3390/ijms26083463, doi:10.3390/ijms26083463. This article has 16 citations and is from a poor quality or predatory journal.

  6. (ong2024agerelatedmaculardegeneration pages 5-7): J. Ong, Jay Chhablani, Mahendra Singh, Riyakshi Negi, Ramachandran Vinayagam, Sang Gu Kang, and Prashant Shukla. Age-related macular degeneration (amd): pathophysiology, drug targeting approaches, and recent developments in nanotherapeutics. Medicina, 60:1647, Oct 2024. URL: https://doi.org/10.3390/medicina60101647, doi:10.3390/medicina60101647. This article has 17 citations and is from a poor quality or predatory journal.

  7. (bhumika2024geneticinsightsinto pages 3-4): Bhumika, Nalini S. Bora, and Puran S. Bora. Genetic insights into age-related macular degeneration. Biomedicines, 12:1479, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071479, doi:10.3390/biomedicines12071479. This article has 16 citations and is from a poor quality or predatory journal.

  8. (bhumika2024geneticinsightsinto pages 10-11): Bhumika, Nalini S. Bora, and Puran S. Bora. Genetic insights into age-related macular degeneration. Biomedicines, 12:1479, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071479, doi:10.3390/biomedicines12071479. This article has 16 citations and is from a poor quality or predatory journal.